Quantcast
Home > Quotes > ADVM

Adverum Biotechnologies, Inc. Common Stock (ADVM) Quote & Summary Data

ADVM 
$5
*  
0.15
2.91%
Get ADVM Alerts
*Delayed - data as of Jul. 20, 2018  -  Find a broker to begin trading ADVM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 5.25 / $ 4.90
Share Volume
404,184
50 Day Avg. Daily Volume
735,379
Previous Close
$ 5.15
52 Week High / Low
$ 8.59 / $ 2.40
Market Cap
311,359,505
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
404,184
50 Day Avg. Daily Volume:
735,379

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.21

Trading Range

The current last sale of $5 is 108.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.25 $ 8.59
 Low: $ 4.90 $ 2.40

Company Description (as filed with the SEC)

We are a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Leveraging our next-generation adeno-associated virus ("AAV")-based directed evolution platform, we generate gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development and in-house manufacturing expertise, specifically in process development, assay development, and current Good Manufacturing Practices ("cGMP") quality control. Our leadership team has significant drug development and gene therapy expertise. We are advancing our robust pipeline of gene therapy product candidates designed to treat rare diseases, alpha-1 antitrypsin ("A1AT") deficiency and hereditary angioedema ("HAE"), as well as wet age-related macular degeneration ("wAMD"). Our pipeline of lead and partnered gene therapy programs is shown below.  ... More ...  

Risk Grade

Where does ADVM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.15
Open Date:
Jul. 20, 2018
Close Price:
$ 5.15
Close Date:
Jul. 20, 2018

Consensus Recommendation

Analyst Info